Literature DB >> 26181495

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?

S Percy Ivy1, Jan H Beumer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26181495      PMCID： PMC4696392          DOI： 10.1001/jamaoncol.2015.1926

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  15 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Authors:  Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

4.  Body-surface area-based chemotherapy dosing: appropriate in the 21st century?

Authors:  Jan H Beumer; Edward Chu; Salvatore J Salamone
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

Review 5.  Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Authors:  Jennifer J Griggs; Pamela B Mangu; Holly Anderson; Edward P Balaban; James J Dignam; William M Hryniuk; Vicki A Morrison; T May Pini; Carolyn D Runowicz; Gary L Rosner; Michelle Shayne; Alex Sparreboom; Lara E Sucheston; Gary H Lyman
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

6.  Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.

Authors:  Janelle M Fauci; Jenny M Whitworth; Kellie E Schneider; Akila Subramaniam; Bin Zhang; Peter J Frederick; Larry C Kilgore; J Michael Straughn
Journal:  Gynecol Oncol       Date:  2011-06-11       Impact factor: 5.482

7.  Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.

Authors:  Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  2002-07-30       Impact factor: 3.333

8.  Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.

Authors:  S V Barrett; J Paul; A Hay; P A Vasey; S B Kaye; R M Glasspool
Journal:  Ann Oncol       Date:  2008-02-13       Impact factor: 32.976

9.  Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Jason D Wright; Chunqiao Tian; David G Mutch; Thomas J Herzog; Shoji Nagao; Keiichi Fujiwara; Matthew A Powell
Journal:  Gynecol Oncol       Date:  2008-04-14       Impact factor: 5.482

10.  Phase I studies with carboplatin at the Royal Marsden Hospital.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.